Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>
Sparad:
| Huvudupphovsman: | Qingsheng Xu (17078830) (author) |
|---|---|
| Övriga upphovsmän: | Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author) |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Liknande verk
Liknande verk
-
Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
av: Qingsheng Xu (17078830)
Publicerad: (2025) -
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
av: Sied Kebir (15048732)
Publicerad: (2025) -
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
av: Sied Kebir (15048732)
Publicerad: (2025) -
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
av: Sied Kebir (15048732)
Publicerad: (2025) -
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
av: Sied Kebir (15048732)
Publicerad: (2025)